Company intelligence / Profile preview

Helen Ilios

Boston, Massachusetts, United Stateshelenilios.com ↗

Ownership: Private
Development stage: Other

Overview

Ilios Therapeutics has developed a rationally designed, first-in-class multi-functional small molecule platform that targets three key mechanisms in neurodegenerative diseases. The lead program is focused on ALS/FTD and is entering preclinical biological testing. No clinical results are available yet.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Partnerships

No major pharmaceutical partnerships disclosed; seeking collaborations to expand pipeline.

Beyond the preview

Go deeper on Helen Ilios.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Helen Ilios.

Explore the full profile